Market Research Report
Prefilled Syringes Market (5th Edition), 2020-2030
|Published by||ROOTS ANALYSIS||Product code||283286|
|Published||Content info||554 Pages
Delivery time: 1-2 business days
|Prefilled Syringes Market (5th Edition), 2020-2030|
|Published: January 31, 2020||Content info: 554 Pages||
Case Study: The market is also characterized by the presence of many contract service providers, spread across the world, offering fill / finish services in prefilled syringes.
"We are seeing an increased demand in the emerging markets, particularly within the BRICS nations, namely Brazil, Russia, India, China and South Africa. North Africa and the Middle East also present a similar scenario, characterized by a growth rate of 10-18% for prefilled syringes." - Marketing Director, a large-sized company.
According to experts in the healthcare industry, one in three adults are estimated to be suffering from some type of chronic clinical condition, such as multiple sclerosis, diabetes, rheumatoid arthritis and cardiovascular diseases. Chronic clinical conditions are considered to be among the leading causes of death and disability across the world. Typically, in such cases, individuals are required to medicate on a daily basis. In addition to the cost of medication, such individuals are also burdened with a deteriorating quality of life, and often struggle with medication adherence. According to the US Centers for Disease Control (CDC), the overall annual expense incurred by those living with chronic diseases is steadily growing and is currently estimated to be more than USD 3 trillion. The development and commercialization of self-administrable dosage forms of drugs indicated to treat chronic clinical conditions has made a significant positive impact not only on the healthcare expenses borne by patients but also on compliance to prescribed therapeutic regimens. As the number of patients suffering from such disorders increase, the demand for more convenient and patient friendly drug delivery solutions is also on the rise.
The ‘Prefilled Syringes Market (5th edition), 2019-2030' report features an extensive study of the current market landscape of prefilled syringes and the likely future opportunities associated with such devices, over the next 10-12 years. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to evaluate the current market size and the future opportunity within the prefilled syringes market. Based on various relevant parameters, such as the number of commercialized combination products, annual adoption rate, and expected pricing, we have provided an informed estimate of the likely evolution of the market over the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] therapeutic area (blood disorders, infectious diseases, autoimmune disorders, oncology disorders, neurological disorders, ophthalmic diseases and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)).
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the prefilled syringes market in the mid to long term.
Chapter 3 provides an introduction to the concept of prefilled syringes, including details on their origin, various affiliated components (such as barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap), fabrication material (glass and plastic), manufacturing-related information, and other critical attributes and features. In addition, the chapter includes a discussion highlighting the future of prefilled syringes.
Chapter 4 provides an overview of around 80 prefilled syringes that are available in the market and provides details on the companies that manufacture such products. It features analyses of the prefilled syringes, based on various parameters, such as type of material (glass and plastic), number of barrel chambers (dual chamber and single chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes a discussion on the technological advances of prefilled syringes that have taken place in the recent past.
Chapter 5 presents a product competitiveness analysis of glass and plastic prefilled syringes (separately) based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 6 includes detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter also features short profiles of some of the small and mid-sized manufacturers, highlighting brief overview of the company, product portfolio and recent developments (if available).
Chapter 7 highlights the growing concerns associated with needlestick injuries and the various steps (including regional and global legislations) that have been taken to prevent sharps related mishaps. One of the important risk mitigation strategies covered in this chapter is the installation of safety features in upcoming versions of prefilled syringes. In addition, the chapter provides information on syringe-related safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.
Chapter 8 presents overview of the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the prefilled syringes regulatory requirements and the role of regulatory bodies in the approval of syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.
Chapter 9 provides details on the various pipeline and approved products that are being tested or available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. It features a detailed analysis of these drugs, based on the various parameters, such as the target therapeutic area(s), phase of development, type of drug molecule, route of administration, approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers, year of their establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes case studies of top two marketed drugs available in prefilled syringes, namely Humira® and Enbrel®.
Chapter 10 features a discussion on the most commonly targeted therapeutic indications, including information on the approved / marketed injectable drug products available for the treatment of such clinical conditions (across different target therapeutic areas) and their respective biosimilars.
Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via prefilled syringes in the future. It is worth highlighting that this list has been compiled based on various parameters, such as route of administration, target therapeutic indication(s), other available dosage forms (in case of marketed drugs), type of drug molecule and drug sales of the approved product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a prefilled syringe in the future was estimated using the weighted average method. Additionally, the chapter features an insightful analysis, highlighting potential strategic partners (primarily drug developers) for prefilled syringes manufacturers, based on multiple parameters, such as pipeline strength, targeted therapeutic indications, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to develop combination products.
Chapter 12 highlights top ten big pharma players engaged or likely to be engaged in the domain of prefilled syringes. It features a benchmarking of the companies based on parameters, such as current adoption (based on number of approved and development-stage prefilled syringe combination products) and likely future adoption (based on potential likely early and late stage pipelines), target therapeutic area(s), and type of drug molecules.
Chapter 13 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and prefilled contrast agent delivery systems. For each type of specialty syringe, we have provided a brief overview and details on the different products that are available in the market and their advantages.
Chapter 14 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advancements in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual chambered syringe systems. The chapter also highlights novel lubrication and sterilization technologies.
Chapter 15 presents an insightful market forecast analysis, highlighting the future potential of the prefilled syringes market till the year 2030. We have segregated the opportunity of the market on the basis of [A] therapeutic area (blood disorders, infectious diseases, autoimmune disorders, oncology disorders, neurological disorders, ophthalmic diseases and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)). The analysis presents 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.
Chapter 16 features a detailed discussion on the various factors that are anticipated to drive growth within the prefilled syringes market, such as the rise in preference for self-administration of medication, increase in incidence of chronic diseases, evolving patient landscape, introduction and growing adoption of biologics / biosimilars, initiatives focused on the prevention of needlestick injuries and the various potential applications of prefilled syringes.
Chapter 17 provides a detailed SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.
Chapter 18 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler, Lonstroff, Ompi, West Pharmaceutical and Jiangsu Hualan New Pharmaceutical Material.
Chapter 19 provides an overview of the landscape of pharmaceutical companies that offer fill / finish contract services for prefilled syringes. It includes information related to over 100 contract service providers that are currently active in this domain. It features in-depth analyses based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of drug molecules filled (small molecule and biologics), year of establishment, company size and geographical location of the service providers.
Chapter 20 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Elcam Medical, Nuance Designs, Owen Mumford, SHL Group, Union Medico and Ypsomed.
Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 22 is a collection of transcripts of interviews conducted with representatives from renowned organizations that are engaged in the prefilled syringes manufacturing domain. In this chapter, we have presented the details of our conversations with Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical), Marco Pederiva (Marketing & Sales Director, Lonstroff) and Anonymous (Chief Executive Officer, Small-sized Medical Device Company).
Chapters 23 is an appendix that provides tabulated data and numbers for all the figures included in the report.
Chapter 24 is an appendix that contains the list of companies and organizations mentioned in the report.
The following companies and organizations have been mentioned in the report.